We would love to hear your thoughts about our site and services, please take our survey here.
Understatement at this moment. Have noted the short positions have gradually unwound & they could be history at this rate.
Not technical, but this looks like a good test. Anyone with a view on it (monkshood, gmcc, chiron ab8 etc).
https://www.medicaldevice-network.com/news/uk-excalibur-covid-19-antigen-test/
My own thoughts so totally agree. For all forms of international travel Covid testing will be around for a long time. But, also, tests will be developed for a range of viruses as & when they appear, & from what we are told proprietry affimers can be identified & produced very (relatively) quickly.
If avacta get this right, whether as a colloboration or independently, ................................................
Wyndrum (12:46) you are too optimistic. Why does it have to have an endpoint? 'Flu' hasn't, so why should covid? It functions well in all environments & is not dependent on time of year. Wouldn't surprise if it became endemic as unlikely the world's population will (eventually) be vaccinated. People will be travelling country to country (eg brazil - japan), so unless covid is eradicated worlwide, it will, in one form or another, be around for a long long time.
Very likely Richob, & why wouldn't it be able to develop multiple highly infectious variations/mutations. It's shown here & SA what it's capable of, so why not anywhere/everywhere. In one form or another think this virus is going to be around a long time.
For info I posted a link to his linkedin profile earlier. On there he includes his cv according to which he is (still) on contract at Pharmaxis australia. Also Pharmaxis list him as a non ex director http://www.pharmaxis.com.au/about/corporate-directory/
Not gardening leave according to his linkedin profile. His cv is listed there: https://www.linkedin.com/in/neil-graham-236769/
Nasdaq has been constantly behind AIM. I think the peak there was +/- $16.80 while AIM was +/-£3. Considering 5 for 1 adr equates to $3.36. Nasdaq will become very interesting when/if very positive news is released on any of tils product lines, or, with concrete interest from third parties, or, when 'shorts' finally decide to close. Any 2 would probably have a explosive effect. Whatever happens in due course, those issued with accustem shares have added value.
Any poster have an idea of the value/identity of the add interests (other than Mpokoto). They seem to be gold related. http://armadalecapitalplc.com/gold
Nelson, you may not be as 'spiked' as you think. My guess is you got accustom shares ,so when they are floated their value can be added to tils sp. 5p, 10p, 50p, £1, who knows, whatever it is, it will sooth the pain & add another dimension to the story.
from rns 21 dec "In addition, the Group has made excellent recent progress with its SARS-CoV-2 lateral flow rapid antigen test programme and we anticipate data from the first clinical trial soon. Our clinical evaluation of the BAMSTM laboratory assay is ongoing at two UK clinical sites that Avacta has established and we have made significant commercial progress for all of our coronavirus testing solutions, establishing scalable routes to market for these products to meet the anticipated very high demand. I look forward to reporting on progress on all these fronts in the New Year and to a very exciting 2021 for the Group."
from rns 23 nov "In preparation for clinical validation of the lateral flow test Avacta is working on both saliva and anterior nasal swab samples. Anterior nasal swabs sample the easily accessible parts of the nose and are therefore painless and straightforward to administer, unlike nasopharyngeal swabs which are generally regarded as painful and unpleasant. Avacta and its partners will continue to develop both sampling methods in parallel in order to bring high performance COVID-19 tests to market quickly to suit a range of use cases. "
From rns 23 nov "In preparation for clinical validation of the lateral flow test Avacta is working on both saliva and anterior nasal swab samples. Anterior nasal swabs sample the easily accessible parts of the nose and are therefore painless and straightforward to administer, unlike nasopharyngeal swabs which are generally regarded as painful and unpleasant. Avacta and its partners will continue to develop both sampling methods in parallel in order to bring high performance COVID-19 tests to market quickly to suit a range of use cases."
rns 21 dec "In addition, the Group has made excellent recent progress with its SARS-CoV-2 lateral flow rapid antigen test programme". Note it doesn't say 'excellent recent progress with the anterior nasel swab'.
We have 2 tests.
observations re Nasdaq
short volume some 40% yesterday!?
'bot' still active
well above average trading volume again today
looking forward to the (imminent?) (hopefully positive) news & it's effect on the sp